Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

View:
Post by bud13 on Sep 27, 2021 12:43pm

Update?

will we ever get a update on what's going on? This starting date seems like it's not going to happen . The delay before was waiting for a refund from the Aussie's. Now we got it will it disappear before anything happens then we will have another reason for a no start date. I'm hoping not as it will just bring us back to old days. Any thoughts HIgh?
Comment by PTBailey on Sep 27, 2021 1:09pm
Supposedly TSX want clarification on deal between Claritas and Obsidian. This was an email I got from Bob on Sept. 20 and I belive they are expecting things to be cleared up this week. We are still awaiting TSXV approval of the USD $1M convertible debenture financing.   It is a frustrating process for the following reasons: The analyst assigned to our submission stated that ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities